Ixekizumab Overview

Introduction of Ixekizumab

Ixekizumab is a humanized IgG4 monoclonal antibody developed by Eli Lilly & Company for the treatment of autoimmune diseases. It was designed specifically to bind interleukin-17A (IL-17A) and produced by recombinant DNA technology in a recombinant mammalian cell line. With the trade name Taltz, Ixekizumab has been successively approved for marketing in United States, European Union, Canada, Japan, and Australia, for the treatment of autoimmune diseases mainly including plaque psoriasis and psoriatic arthritis.

Mechanism of Action of Ixekizumab

The etiology of psoriasis is not fully known. But IL-17A, a proinflammatory cytokine produced by T helper (Th) 17 cells, plays a key role in the pathogenesis of plaque psoriasis. IL17A levels are elevated in psoriatic lesions; binding of IL17A to the IL-17 receptors on keratinocytes leads to the release of other proinflammatory mediators, which in turn recruit more Th17 cells, neutrophils, dendritic cells, and lymphoid cells.

By binding to IL-17A, ixekizumab inhibits its binding to the IL-17A receptor, thereby inhibiting its pro-inflammatory downstream effects on keratinocytes.

Fig. 1 Mechanism of Action of Ixekizumab

Clinical Projects of Ixekizumab*

Approved Drugs of Ixekizumab**

INN (trade name)	Therapeutic area	Dosage	Strength	Route	Company	Marketing start	Market
Taltz	Plaque psoriasis, Psoriatic arthritis, Pustular Psoriasis, Erythrodermic psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Japan K.K.	March 22, 2016
Taltz	Moderate-to-severe plaque psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly & Co. Ltd.	March 22, 2016
Taltz	Active psoriatic arthritis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly & Co. Ltd.	December 1, 2017
Taltz	Plaque psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Nederland B.V.	April 25, 2016
Taltz	Psoriatic arthritis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Nederland B.V.	January 11, 2018
Taltz	Plaque psoriasis, Psoriatic arthritis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Canada Inc.	August 11, 2016
Taltz	Moderate-to-severe plaque psoriasis	Injection, Solution	80 mg/mL	Subcutaneous	Eli Lilly Australia Pty Ltd	June 9, 2016

What We Provide

Therapeutic Antibody

Ixekizumab

We provide high-quality ixekizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Ixekizumab

** Information presented in the table were collected from the following websites:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/3999442G1
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003943/human_med_001977.jsp
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94193
http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=253893

For research use only. Not intended for any clinical use.